Cost-effectiveness of pneumococcal conjugate vaccine: An update after 7 years of use in the United States

Abstract Seven-valent pneumococcal conjugate vaccine (PCV7) has been in routine use in the United States since 2000 and data have indicated direct and indirect effects of the vaccine. We simulated the effects of PCV7 on children vaccinated during 2000–2006, incorporating direct and indirect effects...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2009-11, Vol.27 (47), p.6483-6494
Hauptverfasser:	Ray, G. Thomas, Pelton, Stephen I, Klugman, Keith P, Strutton, David R, Moore, Matthew R
Format:	Artikel
Sprache:	eng
Schlagworte:	Age Allergy and Immunology Applied microbiology Bacteriology Biological and medical sciences Child, Preschool Children Children & youth Computer Simulation Cost Cost control Cost estimates Ear diseases Fundamental and applied biological sciences. Psychology Health maintenance organizations Heptavalent Pneumococcal Conjugate Vaccine Herd immunity HMOs Hospitalization Humans Infant Microbiology Miscellaneous Models, Economic Otitis Media - epidemiology Otitis Media - prevention & control Pneumococcal conjugate vaccine Pneumococcal Infections - epidemiology Pneumococcal Infections - prevention & control Pneumococcal Vaccines - economics Pneumococcus Pneumonia Population Streptococcus pneumoniae Studies United States - epidemiology Vaccine Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Vaccines, Conjugate - economics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Abstract Seven-valent pneumococcal conjugate vaccine (PCV7) has been in routine use in the United States since 2000 and data have indicated direct and indirect effects of the vaccine. We simulated the effects of PCV7 on children vaccinated during 2000–2006, incorporating direct and indirect effects on incidence of invasive pneumococcal disease (IPD), hospitalized pneumonia and otitis media. Before accounting for indirect effects, PCV7 cost $201,000 per life-year saved. After incorporating indirect effects on IPD, cost per life-year saved was $10,400. The presence of modest additional indirect effects against hospitalized pneumonia and otitis media in children may have resulted in overall cost savings.
ISSN:	0264-410X 1873-2518
DOI:	10.1016/j.vaccine.2009.08.045